Adult-onset Still's disease-pathogenesis, clinical manifestations, and new treatment options

Annals of Medicine

Volumn 47, Issue 1, 2015, Pages 6-14

  Kadavath, Sabeeda ^a   Efthimiou, Petros ^a,b  

^a LINCOLN MEDICAL AND MENTAL HEALTH CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Adult onset Still's disease; FUO (fever of unknown origin); Retrospective study

Indexed keywords

CYTOKINE RECEPTOR ANTAGONIST; DISEASE MODIFYING ANTIRHEUMATIC DRUG; INTERLEUKIN 1 BETA ANTAGONIST; INTERLEUKIN 6 BLOCKING AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; STEROID; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT; CYTOKINE; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT ONSET STILL DISEASE; AMYLOIDOSIS; BLOOD CLOTTING DISORDER; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; DISSEMINATED INTRAVASCULAR CLOTTING; HEMATOLOGIC MALIGNANCY; HUMAN; LUNG DISEASE; MACROPHAGE ACTIVATION SYNDROME; PARANEOPLASTIC SYNDROME; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; STEROID THERAPY; THROMBOCYTOPENIA; ADULT; COMPLICATION; PATHOPHYSIOLOGY; STILL'S DISEASE, ADULT-ONSET;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; CYTOKINES; HUMANS; STILL'S DISEASE, ADULT-ONSET;

EID: 84923305444     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2014.971052     Document Type: Review

References (117)

1. Shoji S, Imamura A, Imai Y, Igarashi A, Yazawa M, Hirahara K, et al. Fever of unknown origin: a review of 80 patients from the Shin'etsu area of Japan from 1986-1992. Intern Med. 1994; 33: 74-6
2. Iikuni Y, Okada J, Kondo H, Kashiwazaki S. Current fever of unknown origin 1982-1992. Intern Med. 1994; 33: 67-73
3. Sipahi OR, Senol S, Arsu G, Pullukcu H, Tasbakan M, Yamazhan T, et al. Pooled analysis of 857 published adult fever of unknown origin cases in Turkey between 1990-2006. Med Sci Monit. 2007; 13: CR318-22
4. Bywaters EG. still's disease in the adult. Ann Rheum Dis. 1971; 30: 121-33
5. Wouters JM, van Der Veen J, van De Putte LB, De Rooij DJ. Adult onset still's disease and viral infections. Ann Rheum Dis. 1988; 47: 764-7
6. Chen DY, Chen YM, Lan JL, Tzang BS, Lin CC, Hsu TC. Signifi cant association of past parvovirus B19 infection with cytopenia in both adult-onset still's disease and systemic lupus erythematosus patients. Clin Chim Acta. 2012; 413: 855-60
7. Fujii T, Nojima T, Yasuoka H, Satoh S, Nakamura K, Kuwana M, et al. Cytokine and immunogenetic profiles in Japanese patients with adult still's disease. Association with chronic articular disease. Rheumatology (Oxford). 2001; 40: 1398-404
8. Choi JH, Suh CH, Lee YM, Suh YJ, Lee SK, Kim SS, et al. Serum cytokine profiles in patients with adult onset still's disease. J Rheumatol. 2003; 30: 2422-7
9. Chen DY, Hsieh TY, Hsieh CW, Lin FJ, Lan JL. Increased apoptosis of peripheral blood lymphocytes and its association with interleukin-18 in patients with active untreated adult-onset still's disease. Arthritis Rheum. 2007; 57: 1530-8
10. Pouchot J, Sampalis JS, Beaudet F, Carette S, Decary F, Salusinsky-Sternbach M, et al. Adult still's disease: manifestations, disease course, and outcome in 62 patients. Medicine. 1991;70:118-36
11. Miller ML, Aaron S, Jackson J, Fraser P, Cairns L, Hoch S, et al. HLA gene frequencies in children and adults with systemic onset juvenile rheumatoid arthritis. Arthritis Rheum. 1985; 28: 146-50
12. Wouters JM, Reekers P, van De Putte LB. Adult-onset still's disease. Disease course and HLA associations. Arthritis Rheum. 1986; 29: 415-18
13. J oung C I, Lee H S, Lee S W, Kim C G, Song Y H, Jun J B, et al. A ssociation between HLA-DR B1 and clinical features of adult onset still's disease in Korea. Clin Exp Rheumatol. 2003; 21: 489-92
14. Kawashima M, Yamamura M, Taniai M, Yamauchi H, Tanimoto T, Kurimoto M, et al. Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset still's disease. Arthritis Rheum. 2001; 44: 550-60
15. Chen DY, Lan JL, Lin FJ, Hsieh TY, Wen MC. Predominance of Th 1 cytokine in peripheral blood and pathological tissues of patients with active untreated adult onset still's disease. Ann Rheum Dis. 2004;63:1300-6
16. Chen DY, Lan JL, Lin FJ, Hsieh TY. ProInflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset still's disease. J Rheumatol. 2004; 31: 2189-98
17. Ishaq M, Nazir L, Riaz A, Alam SM, Shaikh MI. ' The eyes see what the mind knows.'Adult-onset still's disease, acase series and review in a south Asian population. Int J Rheum Dis. 2012;15:e96-100
18. Yamamoto T. Cutaneous manifestations associated with adult-onset still's disease: important diagnostic values. Rheumatol Int. 2012; 32: 2233-7
19. Fitzgerald AA, Leclercq SA, Yan A, Homik JE, Dinarello CA. Rapid responses to anakinra in patients with refractory adult-onset still's disease. Arthritis Rheum. 2005; 52: 1794-803
20. Kotter I, Wacker A, Koch S, Henes J, Richter C, Engel A, et al. Anakinra in patients with treatment-resistant adult-onset still's disease: four case reports with serial cytokine measurements and a review of the literature. Semin Arthritis Rheum. 2007; 37: 189-97
21. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med. 2005;201:1479-86
22. Giampietro C, Fautrel B. Anti-interleukin-1 agents in adult onset still's disease. Int J Inflam. 2012;2012:317820
23. Chen DY, Lin CC, Chen YM, Lan JL, Hung WT, Chen HH, et al. Involvement of TLR7 MyD88-dependent signaling pathway in the pathogenesis of adult-onset still's disease. Arthritis Res Ther. 2013; 15: R39
24. Chen DY, Lin CC, Chen YM, Lan JL, Hung WT, Chen HH, et al. Involvement of TLR7 MyD88-dependent signaling pathway in the pathogenesis of adult-onset still's disease. Arthritis Res Ther. 2013; 15: R39
25. Chen DY, Chen YM, Lan JL, Lin CC, Chen HH, Hsieh CW. Potential role of Th 17 cells in the pathogenesis of adult-onset still's disease. Rheumatology (Oxford). 2010; 49: 2305-12
26. Horai R, Saijo S, Tanioka H, Nakae S, Sudo K, Okahara A, et al. Development of chronic Inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-defi cient mice. J Exp Med. 2000;191:313-20
27. Nicklin MJ, Hughes DE, Barton JL, Ure JM, Duff GW. Arterial Inflammation in mice lacking the interleukin 1 receptor antagonist gene. J Exp Med. 2000; 191: 303-12
28. Reddy S, Jia S, Geoff rey R, Lorier R, Suchi M, Broeckel U, et al. An autoInflammatory disease due to homozygous deletion of the IL1RN locus. N Engl J Med. 2009; 360: 2438-44
29. Aksentijevich I, Masters SL, Ferguson PJ, Dancey P, Frenkel J, van Royen-Kerkhoff A, et al. An autoInflammatory disease with defi ciency of the interleukin-1-receptor antagonist. N Engl J Med. 2009;360:2426-37
30. Min JK, Cho CS, Kim HY, Oh EJ. Bone marrow fi ndings in patients with adult still's disease. Scand J Rheumatol. 2003;32:119-21
31. Kogawa K, Lee SM, Villanueva J, Marmer D, Sumegi J, Filipovich AH. Perforin expression in cytotoxic lymphocytes from patients with hemophagocytic lymphohistiocytosis and their family members. Blood. 2002; 99: 61-6
32. Larson EB. Adult still's disease-recognition of a clinical syndrome and recent experience. West J Med. 1985; 142: 665-71
33. C hen D Y, Lan H H, Hsieh T Y, Chen H H, Lan JL. C rico-thyroid perichondritis leading to sore throat in patients with active adult-onset still's disease. Ann Rheum Dis. 2007; 66: 1264-6
34. Eft himiou P, Paik PK, Bielory L. Diagnosis and management of adult onset still's disease. Ann Rheum Dis. 2006; 65: 564-72
35. Hijikata N, Takayanagi N, Sugita Y, Kawabata Y. Adult-onset still's disease with pulmonary involvement. J Bronchology Interv Pulmonol. 2009;16:277-82
36. Ibn Yacoub Y, Amine B, Laatiris A, Hajjaj-Hassouni N. Bilateral low lobar atelectasis in a young woman with adult-onset still's disease. Rheumatol Int. 2010;30:1639-41
37. Neto N S, Waldrich L, De Carvalho J F, Pereira RM. [ Adult-onset still's disease with pulmonary and cardiac involvement and response to intravenous immunoglobulin]. Acta Reumatol Port. 2009; 34: 628-32
38. Sari I, Birlik M, Binicier O, Akar S, Yilmaz E, Onen F, et al. A case of adult-onset still's disease complicated with diff use alveolar hemorrhage. J Korean Med Sci. 2009; 24: 155-7
39. Lee JB, Kim JW, Lee SS, Kim SJ, Won YH, Lee SC. Adult-onset still's disease with vesiculopustules on the hands and feet. J Korean Med Sci. 2002;17:852-5
40. Sunderkotter C, Frieling U, Nashan D, Metze D. [Adult-onset still's disease and its characteristic rash]. Hautarzt. 1998; 49: 920-4
41. Lee JY, Yang CC, Hsu MM. Histopathology of 41. persistent papules and plaques in adult-onset still's disease. J Am Acad Dermatol. 2005;52:1003-8
42. Crispin JC, Martinez-Banos D, Alcocer-Varela J. Adult-onset Still disease as the cause of fever of unknown origin. Medicine. 2005; 84: 331-7
43. Takahashi A, Abe K, Yokokawa J, Iwadate H, Kobayashi H, Watanabe H, et al. Clinical features of liver dysfunction in collagen diseases. Hepatol Res. 2010; 40: 1092-7
44. Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, et al. Preliminary criteria for Classification of adult still's disease. J Rheumatol. 1992; 19: 424-30
45. Calabro JJ, Marchesano JM. Fever associated with juvenile rheumatoid arthritis. N Engl J Med. 1967; 276: 11-18
46. Reginato AJ, Schumacher HR Jr, Baker DG, O' Connor CR, Ferreiros J. Adult onset still's disease: experience in 23 patients and literature review wiThemphasis on organ failure. Semin Arthritis Rheum. 1987;17:39-57
47. Cush JJ, Medsger TA Jr, Christy WC, Herbert DC, Cooperstein LA. Adult-onset still's disease. Clinical course and outcome. Arthritis Rheum. 1987; 30: 186-94
48. Goldman JA, Beard MR, Casey HL. Acute febrile juvenile rheumatoid arthritis in adults: cause of polyarthritis and fever. South Med J. 1980;73:555-63
49. Vanderschueren S, Hermans F, De Munter P, Knockaert D. Adult-onset still's disease: still a diagnosis of exclusion. A nested case-control study in patients with fever of unknown origin. Clin Exp Rheumatol. 2012;30:514-19
50. Fautrel B, Zing E, Golmard JL, Le Moel G, Bissery A, Rioux C, et al. Proposal for a new set of Classification criteria for adult-onset Still disease. Medicine (Baltimore). 2002; 81: 194-200
51. Cush JJ. Adult-onset still's disease. Bull Rheum Dis. 2000; 49: 1-4
52. Ohta A, Yamaguchi M, Kaneoka H, Nagayoshi T, Hiida M. Adult still's disease: review of 228 cases from the literature. J Rheumatol. 1987;14:1139-46
53. Louthrenoo W, Aramsareewong T, Sukitawut W. Adult onset still's disease: clinical features and outcome in 16 Th ai patients. J Clin Rheumatol. 2001; 7: 301-7
54. M ehrpoor G, Owlia M B, Soleimani H, Ayatollahi J. Adult-onset still's disease: a report of 28 cases and review of the literature. Mod Rheumatol. 2008; 18: 480-5
55. Tanaka S, Matsumoto Y, Ohnishi H, Maeda M, Nishioka K, Kashiwazaki S, et al. [Comparison of clinical features of childhood and adult onset still's disease]. Ryumachi [Rheumatism]. 1991; 31: 511-18
56. Pay S, Turkcapar N, Kalyoncu M, Simsek I, Beyan E, Ertenli I, et al. A multicenter study of patients with adult-onset still's disease compared with systemic juvenile idiopathic arthritis. Clin Rheumatol. 2006;25:639-44
57. Kontzias A, Eft himiou P. The use of Canakinumab, anovel IL-1beta long-acting inhibitor, in refractory adult-onset still's disease. Semin Arthritis Rheum. 2012; 42: 201-5
58. Hagihara K, Nishikawa T, Sugamata Y, Song J, Isobe T, Taga T, et al. Essential role of STAT3 in cytokine-driven NF-kappaB-mediated serum amyloid A gene expression. Genes Cells. 2005; 10: 1051-63
59. Hagihara K, Nishikawa T, Isobe T, Song J, Sugamata Y, Yoshizaki K. IL-6 plays a critical role in the synergistic induction of human serum amyloid A (SAA) gene when stimulated with proInflammatory cytokines as analyzed with an SAA isoform real-time quantitative RTPCR assay system. Biochem Biophys Res Commun. 2004; 314: 363-9
60. Shibuya Y, Matuo K, Kawada T, Kosugi T, Gomi T. [Adult onset still's disease associated esophageal cancer: a case report]. Ryumachi. 2003; 43:577-82
61. Otrock ZK, Hatoum HA, Uthman IW, Taher AT, Saab S, Shamseddine AI. Non-Hodgkin's lymphoma in a woman with adultonset still's disease: a case report. J Med Case Rep. 2008;2:73
62. Novak S, Anic F, Luke-Vrbanic TS. Extremely high serum ferritin levels as a main diagnostic tool of adult-onset still's disease. Rheumatol Int. 2012;32:1091-4
63. Chen DY, Chuang HC, Lan JL, Chen YM, Hung WT, Lai KL, et al. Germinal center kinase-like kinase (GLK/MAP4K3) expression is increased in adult-onset still's disease and may act as an activity marker. BMC Med. 2012; 10: 84
64. K im H A, An JM, Nam JY, Jeon JY, Suh CH. Serum S100A8/A9, but not follistatin-like protein 1 and interleukin 18, may be a useful biomarker of disease activity in adult-onset still's disease. J Rheumatol. 2012;39:1399-406
65. Jung SY, Park YB, Ha YJ, Lee KH, Lee SK. Serum calprotectin as a marker for disease activity and severity in adult-onset still's disease. J Rheumatol. 2010; 37: 1029-34
66. Linde B, Oelzner P, Katenkamp K, Hein G, Wolf G. [Fulminate liver failure in a 39-year-old female patient with leukocytosis, unclear fever, and arthralgic pain]. Med Klin (Munich). 2007; 102: 846-51
67. Antoniou KM, Margaritopoulos GA, Giannarakis I, Choulaki C, Fountoulakis N, Siafakas NM, et al. Adult onset still's disease: a case report with a rare clinical manifestation and pathophysiological correlations. Case Rep Med. 2013; 2013: 981232
68. Masson C, Le Loet X, Liote F, Renou P, Dubost JJ, Boissier MC, et al. Adult still's disease. Part II. Management, outcome, and prognostic factors. Rev Rhum Engl Ed. 1995;62:758-65
69. Bisagni-Faure A, Job-Deslandre C, Menkes CJ. Intravenous methylprednisolone pulse therapy in still's disease. J Rheumatol. 1992; 19: 1487-8
70. Kalliolias GD, Georgiou PE, Antonopoulos IA, Andonopoulos AP, Liossis SN. Anakinra treatment in patients with adult-onset still's disease is fast, Effective, safe and steroid sparing: experience from an uncontrolled trial. Ann Rheum Dis. 2007; 66: 842-3
71. Maier J, Birkenfeld G, Pfirstinger J, Scholmerich J, Fleck M, Bruhl H. Effective treatment of steroid refractory adult-onset still's disease with anakinra. J Rheumatol. 2008; 35: 939-41
72. Raff einer B, Botsios C, Dinarello C, Ometto F, Punzi L, Ramonda R. Adult-onset still's disease with myocarditis successfully treated with the interleukin-1 receptor antagonist anakinra. Joint Bone Spine. 2011;78:100-1
73. Lequerre T, Quartier P, Rosellini D, Alaoui F, De Bandt M, Mejjad O, et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis. 2008; 67: 302-8
74. Dinarello CA. Blocking IL-1 in systemic Inflammation. J Exp Med. 2005;201:1355-9
75. A arntzen E H, van Riel P L, Barrera P. R efractory adult onset still's disease and hypersensitivity to non-steroidal anti-Inflammatory drugs and cyclo-oxygenase-2 inhibitors: are biological agents the solution?. Ann Rheum Dis. 2005; 64: 1523-4
76. Cohen SB, Moreland LW, Cush JJ, Greenwald MW, Block S, Shergy WJ, et al. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), arecombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis. 2004; 63: 1062-8
77. Vasques Godinho FM, Parreira Santos MJ, Canas Da Silva J. Refractory adult onset still's disease successfully treated with anakinra. Ann Rheum Dis. 2005; 64: 647-8
78. Naumann L, Feist E, Natusch A, Langen S, Krause A, Buttgereit F, et al. IL1-receptor antagonist anakinra provides long-lasting Efficacy in the treatment of refractory adult-onset still's disease. Ann Rheum Dis. 2010;69:466-7
79. Laskari K, Tzioufas AG, Moutsopoulos HM. Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with still's disease: a case-series study. Arthritis Res Ther. 2011; 13: R91
80. Stahl N, Radin A, Mellis S. R ilonacept-CAPS and beyond. A nn N Y Acad Sci. 2009; 1182: 124-34
81. Dhimolea E. Canakinumab. MAbs. 2010; 2: 3-13
82. Alten R, Gomez-Reino J, Durez P, Beaulieu A, Sebba A, Krammer G, et al. Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-fi nding study. BMC Musculoskelet Disord. 2011;12:153
83. Ruperto N, Quartier P, Wulff raat N, Woo P, Ravelli A, Mouy R, et al. A phase II, multicenter, open-label study evaluating dosing and preliminary safety and Efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. A rthritis Rheum. 2 012; 6 4: 5 57-6 7
84. Petryna O, Cush JJ, Eft himiou P. I L-1 Trap rilonacept in refractory adult onset still's disease. Ann Rheum Dis. 2012; 71: 2056-7
85. Kim HA, Sung JM, Suh CH. Therapeutic responses and prognosis in adult-onset still's disease. Rheumatol Int. 2012;32:1291-8
86. Song SN, Iwahashi M, Tomosugi N, Uno K, Yamana J, Yamana S, et al. Comparative evaluation of the Effects of treatment with tocilizumab and TNF-alpha inhibitors on serum hepcidin, anemia response and disease activity in rheumatoid arthritis patients. Arthritis Res Ther. 2013;15:R141
87. Puechal X, DeBandt M, Berthelot JM, Breban M, Dubost JJ, Fain O, et al. Tocilizumab in refractory adult still's disease. Arthritis Care Res (Hoboken). 2011; 63: 155-9
88. De Bandt M, Saint-Marcoux B. T ocilizumab for multirefractory adult-onset still's disease. Ann Rheum Dis. 2009; 68: 153-4
89. Kobayashi M, Takahashi Y, Yamashita H, Kaneko H, Mimori A. Benefi t and a possible risk of tocilizumab therapy for adult-onset still's disease accompanied by macrophage-activation syndrome. Mod Rheumatol. 2011; 21: 92-6
90. De Boysson H, Fevrier J, Nicolle A, 90. Auzary C, Geff ray L. T ocilizumab in the treatment of the adult-onset still's disease: current clinical evidence. Clin Rheumatol. 2013; 32: 141-7
91. Sakai R, Nagasawa H, Nishi E, Okuyama A, Takei H, Kurasawa T, et al. Successful treatment of adult-onset still's disease with tocilizumab monotherapy: two case reports and literature review. Clin Rheumatol. 2012;31:569-74
92. Husni ME, Maier AL, Mease PJ, Overman SS, Fraser P, Gravallese EM, et al. Etanercept in the treatment of adult patients with still's disease. Arthritis Rheum. 2002; 46: 1171-6
93. Kraetsch HG, Antoni C, Kalden JR, Manger B. Successful treatment of a small cohort of patients with adult onset of still's disease with Infliximab: first experiences. Ann Rheum Dis. 2001;60(Suppl 3):iii55-7
94. C avagna L, Caporali R, Epis O, Bobbio-Pallavicini F, Montecucco C. Infliximab in the treatment of adult still's disease refractory to conventional therapy. Clin Exp Rheumatol. 2001; 19: 329-32
95. Fautrel B, Sibilia J, Mariette X, Combe B. Tumour necrosis factor alpha blocking agents in refractory adult still's disease: an observational study of 20 cases. Ann Rheum Dis. 2005; 64: 262-6
96. Agarwal S, Moodley J, Ajani Goel G, Theil KS, Mahmood SS, Lang RS. A rare trigger for macrophage activation syndrome. Rheumatol Int. 2011;31:405-7
97. Eft himiou P, Moorthy LN, Mavragani CP, Skokos D, Fautrel B. Adult onset still's disease and autoInflammation. Int J Inflam. 2012;2012:964751
98. Benucci M, Li GF, Del Rosso A, Manfredi M. Adalimumab (anti- TNF-alpha) therapy to improve the clinical course of adult-onset still's disease: the first case report. Clin Exp Rheumatol. 2005; 23: 733
99. Debiais S, Maillot F, Luca L, Buret J, Fautrel B, Renard JP. Efficacy of anakinra in a case of refractory Still disease. J Clin Rheumatol. 2008;14:357-8
100. Gattorno M, Piccini A, Lasiglie D, Tassi S, Brisca G, Carta S, et al. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2008; 58: 1505-15
101. Giampietro C, Ridene M, Lequerre T, Costedoat Chalumeau N, Amoura Z, Sellam J, et al. Anakinra in adult-onset still's disease: longterm treatment in patients resistant to conventional therapy. Arthritis Care Res (Hoboken). 2013; 65: 822-6
102. K ishida D, Okuda Y, Onishi M, Takebayashi M, Matoba K, Jouyama K, et al. Successful tocilizumab treatment in a patient with adult-onset still's disease complicated by chronic active hepatitis B and amyloid A amyloidosis. Mod Rheumatol. 2011; 21: 215-18
103. Yoshimura M, Makiyama J, Koga T, Miyashita T, Izumi Y, Torigoshi T, et al. Successful treatment with tocilizumab in a patient with refractory adult-onset still's disease (AOSD). Clin Exp Rheumatol. 2010; 28: 141-2
104. Perdan-Pirkmajer K, Praprotnik S, Tomsic M. A case of refractory adult-onset still's disease successfully controlled with tocilizumab and a review of the literature. Clin Rheumatol. 2010;29:1465-7
105. Th onhofer R, Hiller M, Just H, Trummer M, Siegel C, Dejaco C. Treatment of refractory adult-onset still's disease with tocilizumab: report of two cases and review of the literature. Rheumatol Int. 2011;31:1653-6
106. A lten R, Maleitzke T. T ocilizumab: a novel humanized anti-interleukin 6 (IL-6) receptor antibody for the treatment of patients with non- RA systemic, Inflammatory rheumatic diseases. Ann Med. 2013; 45: 357-63
107. Franchini S, Dagna L, Salvo F, Aiello P, Baldissera E, Sabbadini MG. Efficacy of traditional and biologic agents in different clinical phenotypes of adult-onset still's disease. Arthritis Rheum. 2010;62:2530-5
108. Michel M, Duvoux C, Hezode C, Cherqui D. Fulminant hepatitis aft er Infliximab in a patient with hepatitis B virus treated for an adult onset still's disease. J Rheumatol. 2003; 30: 1624-5
109. Kumari R, Uppal SS. Prolonged remission in adult-onset still's disease wiThetanercept. Clin Rheumatol. 2006;25:106-8. PMID: 15856368
110. Serratrice J, Granel B, Disdier P, Weiller PJ, Dussol B. Resolution wiThetanercept of nephrotic syndrome due to renal AA amyloidosis in adult still's disease. Am J Med. 2003; 115: 589-90
111. Kuek A, Weerakoon A, Ahmed K, Ostor AJ. Adult-onset still's disease and myocarditis: successful treatment with intravenous immunoglobulin and maintenance of remission wiThetanercept. Rheumatology (Oxford). 2007;46:1043-4
112. Mehta BM, Hashkes PJ, Avery R, Deal CL. A 21-year-old man with still's disease with fever, rash, and pancytopenia. Arthritis Care Res (Hoboken). 2010; 62: 575-9
113. Asherson RA, Pascoe L. Adult onset still's disease: response to Enbrel. Ann Rheum Dis. 2002; 61: 859-60; author reply 60
114. Kokkinos A, Iliopoulos A, Greka P, Eft hymiou A, Katsilambros N, Sfi kakis PP. Successful treatment of refractory adult-onset still's disease with Infliximab. A prospective, non-comparative series of four patients. Clin Rheumatol. 2004; 23: 45-9
115. Fujii T, Akizuki M, Kameda H, Matsumura M, Hirakata M, Yoshida T, et al. Methotrexate treatment in patients with adult onset still's disease-retrospective study of 13 Japanese cases. Ann Rheum Dis. 1997;56:144-8
116. Fautrel B, Borget C, Rozenberg S, Meyer O, Le Loet X, Masson C, et al. Corticosteroid sparing Effect of low dose methotrexate treatment in adult still's disease. J Rheumatol. 1999;26:373-8
117. Kontzias A, Eft himiou P. Adult-onset still's disease: pathogenesis, clinical manifestations and therapeutic advances. Drugs. 2008; 68: 319-37